Home › Compound Library › Pibrentasvir

Pibrentasvir

Antiviralprescriptionoral · inferred

Pan-genotypic HCV NS5A inhibitor; component of Mavyret (glecaprevir/pibrentasvir). High barrier to resistance; typically 3 tablets daily (each 40 mg pibrentasvir + 100 mg glecaprevir).

Projected serum levels — 120 mg, once daily

Pibrentasvir
Pibrentasvir modeled serum levels, 120 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Pibrentasvir modeled serum levels with a loading dose of 157 mg, then 120 mg once daily The first dose is larger so levels approach steady state faster. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 120 mg once daily (oral).

Loading schedule: 157 mg on day 1, then 120 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 3.1 mg, trough ≈ 0.96 mg body load. Population-based estimate over 15 days for a 120 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antiviral
Route modeled
Oral
Model confidence
inferred
Half-life
13 h
Common dose
120 mg
Suggested maximum
120 mg/day
Reference dose range
60–120 mg (single dose)
Suggested cadence
once daily
Validated against
120 mg oral — Cmax 0.11 mg/L at 5 h

Documented interactions

  • danger
    Levothyroxine (Synthroid) + Pibrentasvir Protein binding

    Pibrentasvir may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free concentration…

  • warning
    Apigenin + Pibrentasvir Protein binding

    Apigenin may displace Pibrentasvir from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Aripiprazole (Abilify) + Pibrentasvir Protein binding

    Aripiprazole (Abilify) may displace Pibrentasvir from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Armour Thyroid (Desiccated Thyroid Extract) + Pibrentasvir Protein binding

    Pibrentasvir may displace Armour Thyroid (Desiccated Thyroid Extract) from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Astaxanthin + Pibrentasvir Protein binding

    Astaxanthin may displace Pibrentasvir from plasma protein binding sites, transiently raising free drug concentration.

  • warning
    Atomoxetine (Strattera) + Pibrentasvir Protein binding

    Atomoxetine (Strattera) may displace Pibrentasvir from plasma protein binding sites, transiently raising free drug concentration.

Serum checks 297 modeled interaction pairings for pibrentasvir across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-Infected Adults Lin CW et al. · Clinical Pharmacokinetics, 2019 DOI

    Population PK of the glecaprevir/pibrentasvir FDC; pibrentasvir has long t½ and high tissue distribution.

  2. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection Zeuzem S et al. · New England Journal of Medicine, 2018 DOI

    ENDURANCE pivotal trials supporting the 8-week glec/pib regimen.

2 published studies referenced in the app, each with a plain-language summary.